Ernexa Therapeutics (ERNAW) Operating Expenses (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Operating Expenses data on file, last reported at $5.6 million in Q1 2026.

• Quarterly Operating Expenses rose 104.76% year-over-year to $5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.2 million (down 7.16% YoY) and the FY2025 annual result came in at $9.3 million, down 42.33% from the prior year.
• Operating Expenses rose to $5.6 million in Q1 2026, from $2.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $13.9 million in Q2 2022 to a low of $2.0 million in Q3 2025.
• A 5-year average of $5.0 million and a median of $4.9 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 90.38% — and 2026, when it surged 104.76%.
• Tracing ERNAW's Operating Expenses over 5 years: stood at $4.7 million in 2022, then grew by 20.67% to $5.7 million in 2023, then sank by 52.8% to $2.7 million in 2024, then slipped by 22.39% to $2.1 million in 2025, then soared by 166.95% to $5.6 million in 2026.
• The last three Operating Expenses figures came in at $5.6 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.